Cubist Systematic Strategies LLC Cuts Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Cubist Systematic Strategies LLC decreased its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 13.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,976 shares of the company’s stock after selling 3,149 shares during the period. Cubist Systematic Strategies LLC’s holdings in Dianthus Therapeutics were worth $543,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. SG Americas Securities LLC purchased a new position in Dianthus Therapeutics in the second quarter worth $112,000. WINTON GROUP Ltd purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $265,000. Point72 DIFC Ltd acquired a new position in Dianthus Therapeutics during the second quarter worth about $334,000. Virtu Financial LLC acquired a new position in Dianthus Therapeutics during the first quarter worth about $390,000. Finally, Hussman Strategic Advisors Inc. purchased a new position in Dianthus Therapeutics in the first quarter valued at about $630,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Oppenheimer assumed coverage on Dianthus Therapeutics in a report on Thursday. They issued an “outperform” rating and a $48.00 price target on the stock. Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Robert W. Baird initiated coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They set an “outperform” rating and a $58.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Finally, Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $45.13.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $28.00 on Friday. Dianthus Therapeutics, Inc. has a fifty-two week low of $6.58 and a fifty-two week high of $33.77. The stock has a fifty day moving average of $27.89 and a two-hundred day moving average of $26.22. The company has a market capitalization of $821.77 million, a PE ratio of -4.80 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The business had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.63 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. As a group, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.